How many Galliprant dogs are in the picture? Answer correctfy to win £100 in Amazon Vouchers.

Enter competition


It is open to vets and nurses over the age of 18 working in the UK. See full details of the Terms and conditions. The winner will be notified by email shortly after the competition has closed, so be sure to keep an eye on your inbox. Best of luck!

GALLIPRANT CAN BE USED FOR CANINE OSTEOARTHRITIS (OA) FROM FIRST DIAGNOSIS AND FOR AS LONG AS NEEDED*

Galliprant™ (grapiprant) is a first-in-class prostaglandin receptor antagonist (PRA), a piprant class, non-COX inhibiting NSAID. It specifically targets the EP4 receptor, the primary mediator of canine OA pain.1

GALLIPRANT – A MODE OF ACTION UNLIKE ANY OTHER

Dr Kristin Kirkby Shaw, Surgeon and Rehabilitation Specialist at the Animal Surgical Clinic of Seattle, discusses the piprant class, and how it can change our approach to canine osteoarthritis management.

Sign in or register for MyElanco to watch other videos and see more from the experts.

TREATMENT SUCCESS SEEN BY OWNERS, CONFIRMED BY VETS3

In a field study of client-owned dogs, Galliprant treatment resulted in statistically significant improvements in pain interference and pain severity scores compared to placebo on days 7, 14, 21 and 28** (P ≤0.05 for all).3

The treatment effect for Galliprant is comparable to that of traditional NSAIDs.3,4


  • Prospective, randomised, masked, placebo-controlled, 16-site study
  • Galliprant dosed at 2 mg/kg once daily for 28 days
  • 285 dogs enrolled
  • Dogs that received Galliprant were 2 to 16 years old, weighing 4 to 70 kg
  • Measured in the field study through a validated owner assessment: Canine Brief Pain Inventory (CBPI)*** on days 0, 7, 14, 21, 28
  • Veterinary assessment (total orthopedic scores) were significantly better in dogs treated with Galliprant vs placebo at each visit during the study
  • Improvements continued throughout the study period

Duncan Lascelles, Professor of Small Animal Surgery and Pain Management at North Carolina State University, discusses the clinical evidence for use of Galliprant for osteoarthritis in dogs.

Sign in or register for MyElanco to watch other videos and see more from the experts.

MOST DOGS CAN BE DOSED ONCE A DAY WITH A WHOLE OR HALF TABLET†

Galliprant dosing table


†Galliprant should be dosed on an empty stomach.

Sign in or register for MyElanco to download the Galliprant dosing chart and other useful resources for you and your clients.

WELL-TOLERATED AT DOSES EQUIVALENT TO 15X THE TARGET DOSE5

Mode of action targets canine OA pain while reducing the impact on GI, kidney and liver homeostasis.1,2

  • Galliprant was well-tolerated over 9 months at doses equivalent to 15x the target dose in the target animal safety study5
  • No treatment was stopped or dogs removed from the study due to adverse events5
  • Suitable for dogs as young as 9 months of age and older

LATEST NEWS & MORE ABOUT GALLIPRANT

Galliprant voted best new veterinary product of the year 2019!
Incorporate Galliprant into your canine OA protocol today! Get full details, videos and resources by signing up to MyElanco (for those in the UK). For those in Ireland, please complete this form.

Name of the veterinary medicinal product: Galliprant 20 mg, 60 mg, and 100 mg tablets for dogs. Indication: Galliprant is indicated for the treatment of pain associated with mild to moderate osteoarthritis in dogs. Side effects, precautions, warnings and contraindications: Refer to the product packaging and leaflets for information about side effects, precautions, warnings and contraindications. Storage: Do not store above 30°C. Any half tablets should be stored in the bottle. In order to avoid any accidental ingestion, store tablets out of reach of animals.


Galliprant contains grapiprant. Legal category POM-V (UK) POM (IE).


Further information is available from the Summary of Product Characteristics or datasheet. Advice should always be sought from the medicine prescriber. Information on this veterinary medicinal product is available on the website of the European Medicines Agency https://www.ema.europa.eu. For further information call Elanco Animal Health on +44(0)1256 353131 or write to: Elanco UK AH limited, Form 2, Bartley Way, Bartley Wood Business Park, Hook, RG27 9XA.


Use medicines responsibly www.noah.co.uk/responsible (UK); www.apha.ie (IE).

* As field studies were limited to 28 days, longer-term treatment should be considered carefully and regular monitoring undertaken by the vet.


** Primary study endpoint.


*** The CBPI is a validated questionnaire that asks dog owners four questions about the severity of pain evident in a dog (the pain severity score) and six questions about how pain interferes with a dog’s activity level (the pain interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g., medication, surgery).

  1. Kirkby Shaw, K., Rausch-Derra, L., and Rhodes, L. 2016. "Grapiprant: an EP4 prostaglandin receptor antagonist and novel therapy for pain and inflammation." Vet. Med. Sci. 2: 3-9.
  2. Giorgi M. 2015. CJ-023,423 "(Grapiprant) a Potential Novel Active Compound with Antihyperalgetic Properties for Veterinary Patients". Am. J. Anim. Vet. Sci. 10 (2): 53-56.
  3. Rausch-Derra, L., Huebner, M., Wofford, J., et al. 2016. "A prospective, randomized, masked, placebo-controlled multisite clinical study of grapiprant, an EP4 prostaglandin receptor antagonist (PRA), in dogs with osteoarthritis." J. Vet. Int. Med. 30: 756-763.
  4. CVMP assessment report for Galliprant. 9 Nov. 2017. https://www.ema.europa.eu/documents/assessmentreport/galliprant-epar-public-assessment-report_en.pdf [accessed on July 2019].
  5. Rausch-Derra, L., Huebner, M., and Rhodes, L. 2015. "Evaluation of the safety of long-term, daily oral administration of grapiprant, a novel drug for treatment of osteoarthritis pain and inflammation, in healthy dogs." Am. J. Vet. Res. 76.10: 853-859.

© 2020 Elanco or its affiliates. Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. PM-IE-19-0546 / PM-UK-20-0596